Failure to follow up outpatient test results in a timely manner is a growing patient safety concern. To investigate the follow-up of markedly elevated serum potassium levels in the ambulatory setting, the authors reviewed the medical records of all patients seen in a large primary care practice between September 1, 2003, and August 31, 2004, with potassium levels≥5.8mEq/L. Of the 12914 serum potassium tests performed, there were 109 cases of markedly elevated serum potassium levels in 86 patients. The median potassium level was 5.9mEq/L (range, 5.8-7.3). More than half the patients were recalled to the clinic specifically for repeat testing; however, 25% of patients had no repeat tests until they were seen at routine follow-up visits. The median time to a repeat potassium level was 6 days (range, 0-445). Patients≥65 years old had a lower likelihood of having repeat testingwithin 1 week (odds ratio = 0.38,P= .03).
Poon EG, Gandhi TK, Sequist TD, Murff HJ, Karson AS, Bates DW. “I wish I had seen this test result earlier!”: Dissatisfaction with test result management systems in primary care. Arch Intern Med. 2004;164:2223-2228.
2.
Murff HJ, Gandhi TK, Karson AK, et al. Primary care physician attitudes concerning follow-up of abnormal test results and ambulatory decision support systems. Int J Med Inform. 2003;71:137-149.
3.
Plews-Ogan ML, Nadkarni MM, Forren S, et al. Patient safety in the ambulatory setting. J Gen Intern Med. 2004;19:719-725.
4.
Agency for Health care Research and Quality. Patient fact sheet: 20 tips to help prevent medical error. Available at: http://www.ahrq.gov/consumer/20tips.htm.
5.
Marcus AC, Crane LA, Kaplan CP, et al. Improving adherence to screening follow-up among women with abnormal Pap smears: results from a large clinic-based trial of three intervention strategies. Med Care. 1992;30:216-230.
6.
Marcus AC, Kaplan CP, Crane LA, et al. Reducing loss-to-followup among women with abnormal Pap smears: results from a randomized trial testing an intensive follow-up protocol and economic incentives. Med Care. 1998;36:397-410.
7.
Kaplan CP, Bastani R, Belin TR, Marcus A, Nasseri K, Hu MY. Improving follow-up after an abnormal Pap smear: results from a quasi-experimental intervention study. J Womens Health Gend Based Med. 2000;9:779-790.
8.
Poon EG, Haas JS, Louise Puopolo A, et al. Communication factors in the follow-up of abnormal mammograms. J Gen Intern Med. 2004;19:316-323.
9.
Schepkens H, Vanholder R, Billiouw JM, Lameire N.Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med. 2001;110:438-441.
10.
Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors: how much should we worry?Arch Intern Med. 1998;158:26-32.
11.
Perazella MA, Mahnensmith RL. Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis. J Gen Intern Med. 1997;12:646-656.
12.
Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543-551.
13.
Blake J, Devereux RB. Differential effects of direct antagonism of AII compared to ACE inhibitors on serum potassium levels and azotemia in patients with severe congestive heart failure. Congest Heart Fail. 2000;6:193-196.
14.
Acker CG, Johnson JP, Palevsky PM, Greenberg A.Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. Arch Intern Med. 1998;158:917-924.
15.
Charytan D, Goldfarb DS. Indications for hospitalization of patients with hyperkalemia. Arch Intern Med. 2000;160:1605-1611.
16.
Rimmer JM, Horn JF, Gennari FJ. Hyperkalemia as a complication of drug therapy. Arch Intern Med. 1987;147:867-869.
17.
Rose BD. Treatment of hyperkalemia. In: Up To Date. Vol 13.1. Wellesley, Mass: Up To Date; 2005. Available at: http://uptodate.com.
18.
Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289:1107-1116.
19.
Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. N Engl J Med. 2003;348:1556-1564.
20.
Kravitz RL, Rolph JE, Petersen L.Omission-related malpractice claims and the limits of defensive medicine. Med Care Res Rev. 1997;54:456-471.
21.
Lawthers AG, Pransky GS, Peterson LE, Himmelstein JH. Rethinking quality in the context of persons with disability. Int J Qual Health Care. 2003;15:287-299.
22.
Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med. 1998;338:1516-1520.
23.
Reason J.Human Error. Cambridge, UK: Cambridge University Press; 1990:199-212.
24.
Kuperman GJ, Boyle D, Jha A, et al. How promptly are inpatients treated for critical laboratory results?J Am Med Inform Assoc. 1998;5:112-119.
25.
Poon EG, Wang SJ, Gandhi TK, Bates DW, Kuperman GJ. Design and implementation of a comprehensive outpatient results manager. J Biomed Inform. 2003;36:80-91.
